专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1998019996A1 NITRIC OXIDE DONOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PULMONARY HYPERTENSION AND OTHER INDICATIONS 审中-公开
标题翻译：硝酸氧化合物和药物组合物用于肺动脉高压和其他适应症
公开(公告)号：WO1998019996A1
公开(公告)日：1998-05-14
申请号：PCT/US1997020104
申请日：1997-11-05
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER , THE UNIVERSITY OF AKRON
发明人： CHILDREN'S HOSPITAL MEDICAL CENTER , THE UNIVERSITY OF AKRON , SALZMAN, Andrew, L. , SZABO, Csaba , ROSELLE, Dominick, C. , BRILLI, Richard, J. , KRAFTE-JACOBS, Brian , SMITH, Daniel, J.
IPC分类号： C07C291/04
CPC分类号： C07C291/04 , A61K31/131 , C08F8/30 , C08G73/0213 , Y10S514/929 , Y10S514/944 , Y10S514/946 , Y10S514/947
摘要： The invention is directed to nitric oxide (NO) donor compounds (such as those of formulae 1-4) and to pharmaceutical compositions containing such nitric oxide (NO) donor compounds, for delivering NO to the apical surface of a mucosa, where the nitric oxide is released for passage across the epithelial monolayer of the mucous membrane. The NO donor compounds include polyalkyleneamine NO donors as well as tertiary and quaternary amino aliphatic NO donor compounds. The compounds and compositions of the invention are useful in any situation in which it is desirable to deliver NO across a mucosal surface. For example, the compounds and compositions of the invention are particularly useful in treating pulmonary hypertension, male impotence, and several other specific conditions.
摘要翻译：本发明涉及一氧化氮（NO）供体化合物（如式1-4的化合物）和含有这种一氧化氮（NO）供体化合物的药物组合物，用于将NO输送到粘膜的顶端表面，其中硝酸释放氧化物以通过粘膜的上皮单层。 NO供体化合物包括聚亚烷基亚胺NO供体以及叔氨基脂族NO供体化合物。本发明的化合物和组合物可用于期望通过粘膜表面递送NO的任何情况。例如，本发明的化合物和组合物特别可用于治疗肺动脉高压，男性阳ence以及其他几种特定病症。

2. 发明申请

WO1995031729A1 NUCLEIC ACID SEQUENCES CONTROLLING LUNG CELL-SPECIFIC GENE EXPRESSION 审中-公开
标题翻译：控制肺细胞特异性基因表达的核酸序列
公开(公告)号：WO1995031729A1
公开(公告)日：1995-11-23
申请号：PCT/US1995006244
申请日：1995-05-17
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER
发明人： CHILDREN'S HOSPITAL MEDICAL CENTER , BOHINSKI, Robert, J. , WHITSETT, Jeffrey, A.
IPC分类号： G01N33/574
CPC分类号： C12N15/86 , A61K48/00 , C07K14/4705 , C07K14/785 , C12N15/85 , C12N2710/10343 , C12N2830/00 , C12N2830/008 , C12N2830/85 , Y10T428/2984
摘要： An oligonucleotide which includes at least one nucleic acid sequence which binds to at least one nuclear protein found in lung cells, such as TTF-1 protein. The oligonucleotide may be contained in a vector. The at least one nuclear protein provides for lung cell-specific expression of the vector upon binding of the at least one nucleic acid sequence to the at least one nuclear protein. Such vector may also include genes encoding therapeutic agents, and may be employed for delivering genes encoding therapeutic agents to lung cells.
摘要翻译：包含与肺细胞中发现的至少一种核蛋白结合的至少一个核酸序列的寡核苷酸，例如TTF-1蛋白。寡核苷酸可以包含在载体中。所述至少一种核蛋白在所述至少一种核酸序列与所述至少一种核蛋白结合时提供所述载体的肺细胞特异性表达。此类载体还可以包括编码治疗剂的基因，并且可用于将编码治疗剂的基因递送至肺细胞。

3. 发明申请

WO1994002601A1 NON-NATIVE LIVER GENERATION IN AN ANIMAL WITH IMPAIRED NATIVE LIVER FUNCTION BY CELL IMPLANTATION 审中-公开
标题翻译：通过细胞植入具有不良内源性功能的动物中的非内源性生成
公开(公告)号：WO1994002601A1
公开(公告)日：1994-02-03
申请号：PCT/US1993006830
申请日：1993-07-23
申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , UNIVERSITY OF WASHINGTON , CHILDREN'S HOSPITAL MEDICAL CENTER
发明人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , UNIVERSITY OF WASHINGTON , CHILDREN'S HOSPITAL MEDICAL CENTER , BRINSTER, Ralph, L. , PALMITER, Richard, D. , DEGAN, Jay, L. , SANDGREN, Eric, P.
IPC分类号： C12N15/00
CPC分类号： A01K67/0271
摘要： Animals with impaired native liver function harboring a functioning non-native liver derived from implanted non-native cells, and a method of producing such animals are described.
摘要翻译：描述了具有源自植入的非天然细胞的功能性非天然肝脏的具有受损的本地肝功能的动物及其生产方法。

4. 发明申请

WO1997018816A3 SULFATE CONJUGATES OF URSODEOXYCHOLIC ACID, AND THEIR BENEFICIAL USE IN INFLAMMATORY DISORDERS AND OTHER APPLICATIONS 审中-公开
公开(公告)号：WO1997018816A3
公开(公告)日：1997-05-29
申请号：PCT/US1996018487
申请日：1996-11-19
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER
发明人： CHILDREN'S HOSPITAL MEDICAL CENTER , SETCHELL, Kenneth, D., R.
IPC分类号： A61K31/575

5. 发明申请

WO1996030007A1 MERCAPTO AND SELENO DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE 审中-公开
标题翻译：作为氮氧化物合成酶抑制剂的MERCAPTO和SELENO衍生物
公开(公告)号：WO1996030007A1
公开(公告)日：1996-10-03
申请号：PCT/US1996003838
申请日：1996-03-22
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER
发明人： CHILDREN'S HOSPITAL MEDICAL CENTER , SOUTHAN, Garry, J. , SALZMAN, Andrew, L. , SZABO, Csaba
IPC分类号： A61K31/155
CPC分类号： A61K31/426 , A61K31/155 , A61K31/198 , A61K31/54
摘要： This invention is directed to a pharmacologically acceptable composition for inhibiting nitric oxide synthase in a mammal, which includes a mercapto or seleno derivative and a pharmaceutically acceptable carrier. The invention also concerns a method of inhibiting nitric oxide synthase, selectively inhibiting the inducible isoform of nitric oxide synthase, and treating various conditions where there is an advantage in inhibiting nitric oxide biosynthesis. The method includes the step of administering to a mammal a mercapto or seleno derivative in pure form or in a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及一种用于抑制哺乳动物中的一氧化氮合酶的药学上可接受的组合物，其包括巯基或硒衍生物和药学上可接受的载体。本发明还涉及抑制一氧化氮合酶，选择性抑制一氧化氮合酶诱导型异构体的方法，以及治疗抑制一氧化氮生物合成的优点的各种条件。该方法包括向哺乳动物施用纯形式的巯基或硒衍生物或药学上可接受的载体的步骤。

6. 发明申请

WO1988003764A1 GARMENT FOR SHIELDING LINES CONNECTED TO A PATIENT DURING INVASIVE THERAPY 审中-公开
标题翻译：在入侵治疗期间与患者连接的屏蔽线的服装
公开(公告)号：WO1988003764A1
公开(公告)日：1988-06-02
申请号：PCT/US1987003122
申请日：1987-11-25
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER
发明人： CHILDREN'S HOSPITAL MEDICAL CENTER , DENICOLA, Patricia, J. , GORGONE, Patricia, A.
IPC分类号： A41D13/12
CPC分类号： A41D13/1272 , A61F5/3784 , A61M25/02 , A61M2025/0206 , A61M2025/0246
摘要： A garment for shielding from an infant's head and hands intravenous and gastrostomy lines infused into the infant during invasive therapy. The garment accomplishes its shielding objectives without restraining the infant's head or limbs while promoting mental health and development through free movement and play. The garment generally speaking is a sleeveless wrap-around type vest (5) provided with a cloth tab (40) attached to the interior side of the front of the vest for anchoring a portion of the infused line located underneath the vest when it is positioned on the infant. The vest is also uniquely provided with an opening (21) for permitting portions of the infused line to exit from beneath the vest and with cooperating components attached to the exterior side of the vest for further anchoring portions (50) of the infused line which have exited from beneath the vest via the opening. Since the vest is of the wrap-around type, it conforms comfortably to the torso of the infant, shields the infused lines from the infant's head and limbs and encourages the infant to engage in free movement and play.

7. 发明申请

WO1987006943A1 PULMONARY HYDROPHOBIC SURFACTANT-ASSOCIATED PROTEIN OF 6,000 DALTONS MOLECULAR WEIGHT AND MULTIMERS THEREOF 审中-公开
标题翻译： 6,000道尔顿分子量及其多重性的肺动脉血管表面活性剂相关蛋白
公开(公告)号：WO1987006943A1
公开(公告)日：1987-11-19
申请号：PCT/US1986002258
申请日：1986-10-24
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER
发明人： CHILDREN'S HOSPITAL MEDICAL CENTER , WHITSETT, Jeffrey, A.
IPC分类号： C07K15/06
CPC分类号： G01N33/6884 , A61K38/04 , C07K14/785 , C07K16/18 , A61K31/66 , A61K31/575 , A61K31/685 , A61K2300/00
摘要： Novel, isolated, substantially pure, hydrophobic surfactant-associated protein of 6,000 daltons simple molecular weight (SAP-6). When SAP-6 is combined with lipids, its surfactant-like property imparts to the combination significant pulmonary biophysical activity. Such a combination results in enhanced adsorption of the lipids with properties similar to that of natural pulmonary surfactant material. SAP-6 in combination with lipids is highly useful for replacing or supplementing natural pulmonary surfactant material for reducing or maintaining normal surface tension in the lungs, especially in the lungs of patients suffering from hyaline membrane disease (HMD), or other syndromes associated with the lack or insufficient amounts of natural pulmonary surfactant material. A combination of SAP-6 and lipids may be administered as an aerosol spray or in aqueous normal saline with or without calcium chloride for treating or preventing HMD and other surfactant deficiency states. Also disclosed are methods of isolating the SAP-6 from animal tissue.
摘要翻译：具有6000道尔顿简单分子量（SAP-6）的新型，分离，基本纯净的疏水表面活性剂相关蛋白。当SAP-6与脂质组合时，其类似表面活性剂的特性赋予组合显着的肺生物物理活性。这种组合导致具有与天然肺表面活性剂材料类似的性质的脂质的增强的吸附。与脂质组合的SAP-6非常适用于替换或补充天然肺表面活性剂材料，以降低或维持肺中正常的表面张力，特别是在患有透明膜疾病（HMD）或与其相关的其他综合征的患者的肺中天然肺表面活性物质的量不足或不足。 SAP-6和脂质的组合可以作为气溶胶喷雾剂或含有或不含氯化钙的水性生理盐水施用，用于治疗或预防HMD和其它表面活性剂缺乏状态。还公开了从动物组织分离SAP-6的方法。

8. 发明申请

WO1998003552A2 A MULTIVALENT MAJOR HISTOCOMPATIBILITY COMPLEX PEPTIDE FUSION PROTEIN FOR MODULATING SPECIFIC T CELL FUNCTION 审中-公开
标题翻译：用于调节特异性T细胞功能的多重主要组氨酸复合肽融合蛋白
公开(公告)号：WO1998003552A2
公开(公告)日：1998-01-29
申请号：PCT/US1997012324
申请日：1997-07-15
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER
发明人： CHILDREN'S HOSPITAL MEDICAL CENTER , HIRSCH, Raphael , CULLEN, Constance, M.
IPC分类号： C07K19/00
CPC分类号： C07K16/00 , A61K38/00 , A61K47/6425 , A61K47/646 , A61K47/6811 , C07K14/70539 , C07K2319/00 , C07K2319/30 , Y10S530/807
摘要： The present invention describes a soluble fusion protein composed of a plurality of major histocompatibility complex (MHC) molecules linked together by a stabilizing structure herein referred to as the "linker", the MHC molecules being loaded with a specific peptide or peptides. Such fusion proteins can be used as a method for stimulating or inhibiting specific T cell clones expressing T cell receptors (TCR) restricted to the specific MHC-peptide combination. Such fusion proteins can thus be used as delivery systems to stimulate T cell immunity and as a treatment for diseases such as transplant rejection or autoimmunity.
摘要翻译：本发明描述了由通过本文称为“接头”的稳定结构连接在一起的多个主要组织相容性复合体（MHC）分子组成的可溶性融合蛋白，MHC分子被加载了特定的肽或肽。这样的融合蛋白可以用作刺激或抑制表达限定于特定MHC-肽组合的T细胞受体（TCR）的特异性T细胞克隆的方法。因此，这样的融合蛋白可用作递送系统以刺激T细胞免疫，并用作诸如移植排斥或自身免疫等疾病的治疗。

9. 发明申请

WO1997032575A1 MERCAPTO DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASES 审中-公开
标题翻译：作为CYCLOOXYGENASES的抑制剂的MERCAPTO衍生物
公开(公告)号：WO1997032575A1
公开(公告)日：1997-09-12
申请号：PCT/US1997003279
申请日：1997-03-03
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER
发明人： CHILDREN'S HOSPITAL MEDICAL CENTER , ZINGARELLI, Basilia , SALZMAN, Andrew , SZABO, Csaba
IPC分类号： A61K31/155
CPC分类号： A61K31/155
摘要： This invention is directed to a pharmacologically acceptable composition for inhibiting cyclooxygenase in a mammal, which includes a mercapto derivative and a pharmaceutically acceptable carrier. The invention also concerns a method of inhibiting cyclooxygenase and treating various conditions where there is an advantage in inhibiting prostaglandins biosynthesis. The method includes the step of administering to a mammal a mercapto derivative in pure form or in a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及用于抑制哺乳动物环氧合酶的药学上可接受的组合物，其包括巯基衍生物和药学上可接受的载体。本发明还涉及抑制环加氧酶的方法，并且治疗在抑制前列腺素生物合成方面具有优势的各种条件。该方法包括向哺乳动物施用纯形式的巯基衍生物或药学上可接受的载体的步骤。

10. 发明申请

WO1989002915A1 HUMAN CELL LINES OF EPITHELIAL LUNG ADENOCARCINOMA ORIGIN, HUMAN PROTEINS AND METHODS 审中-公开
标题翻译：人上皮细胞生长因子人原核细胞，人类蛋白质和方法
公开(公告)号：WO1989002915A1
公开(公告)日：1989-04-06
申请号：PCT/US1988003342
申请日：1988-09-28
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER , THE UNITED STATES OF AMERICA as represented by ...
发明人： CHILDREN'S HOSPITAL MEDICAL CENTER , THE UNITED STATES OF AMERICA as represented by ... , WHITSETT, Jeffrey, A. , GAZDAR, Adi, F.
IPC分类号： C12N05/00
CPC分类号： C07K14/785 , C07K16/3023 , C12Q1/6886 , C12Q2600/158
摘要： The present invention relates to novel continuous human adenocarcinoma cell lines of epithelial lung tissue origin that produce fully processed or semi-processed surfactant-associated proteins, e.g., SAP-35 and SPL(Phe). The surfactant-associated proteins confer biological activity to pulmonary surfactant phospholipids and are useful for formulating pulmonary surfactant replacement for, inter alia, diagnosis and therapy of human diseases associated with surfactant deficiency. Exemplary cell lines of the present invention designated as NCI-H441-4, NCI-H820, NCI-H322 and NCI-H1404 are deposited with the American Type Culture Collection (ATCC) of Rockville, Maryland under accession Nos. CRL 9400, CRL 9531, CRL 9532 and CRL 9533, respectively. The present invention also relates to a novel method for regulating the expression of a surfactant-associated protein by cells having the ability to express at least one surfactant-associated protein and/or mRNA encoding therefore by exposing the cells to a regulating agent, such as a glucocorticoid hormone, 8-Br-cAMP or a functional equivalent, to selectively induce or inhibit the expression of a surfactant-associated protein. The present invention is also directed to novel methods to screen for tumor cells of pulmonary epithelial origin which produce surfactant-associated proteins and purifying the proteins from lysates of the cells or the media. The present invention also relates to novel human proteins, Mr=40-46,000, Mr=27-33,000 and Mr=23,000 on SDA-PAGE, which are believed to be precursors of the SPL(Phe) human protein. The SPL(Phe) mRNA initially translates an Mr=40-42,000 preproprotein which is glycosylated at asparagine residues and sialylated resulting in an Mr=40-46,000 SPL(Phe) proprotein. The Mr=27-33,000 protein is a proteolytically cleaved fragment of the Mr=40-46,000 precursor, and the Mr=23,000 protein results from de-glycosylating and de-sialylating the Mr=27-33,000 protein.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式